A Comparison of Infarct Size and Prognosis between Cardiogenic Embolic Infarction and Large Artery Atherosclerotic Infarction



Similar documents
Evaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

Duplex Carotid Sonography in Distinguishing Acute Unilateral Atherothrombotic from Cardioembolic Carotid Artery Occlusion

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

DIAGNOSTIC CRITERIA OF STROKE

Medical Management of Ischemic Stroke: An Update. Siddharth Sehgal, MD Medical Director, TMH Neuroscience Center

STROKE PREVENTION IN ATRIAL FIBRILLATION

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

Listen to Your Heart. What Everyone Needs To Know About Atrial Fibrillation & Stroke. The S-ICD System. The protection you need

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice

A focus on atrial fibrillation

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

Atrial Fibrillation and Heart Failure: A Cause or a Consequence

Cardiology Update 2014

secondary Prevention of Stroke

Vertebrobasilar Disease

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

Non-Valvular Atrial Fibrillation & Anticoagulation Therapy: An Actuarial Study of the Medicare Population

Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS 2 and CHA 2 DS 2 -VASc scores

Inba Clinical Pathway for Local Stroke Network with Helicopter Emergency Medical Service in Chiba, Japan

The author has no disclosures

Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose?

Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses

New in Atrial Fibrillation

The International Agenda for Stroke

Perioperative Bridging in Atrial Fibrillation: Is it necessary?

Atherosclerosis of the aorta. Artur Evangelista

CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)

Neal S. Gaither, MD, FACC, FSCAI. The Sonographer Knows

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

Surgeons Role in Atrial Fibrillation

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

CHA 2 DS 2 -VASc Score and Heart Rate Predict Ischemic Stroke Outcomes in Patients with Atrial Fibrillation

Stroke Prevention in Primary Care

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

Listen to your heart: Good Cardiovascular Health for Life

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Antiplatelet and Antithrombotics From clinical trials to guidelines

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Cardiology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Cardiology

Cilostazol versus Clopidogrel after Coronary Stenting

NCD for Lipids Testing

Prior Authorization Guideline

New Anticoagulants and GI bleeding

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines

Press conference: Rheumatic Heart Disease a forgotten but devastating disease

To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC

Anticoagulation Therapy Update

Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain

ATRIAL FIBRILLATION: Scope of the Problem. October 2015

Stroke Coding Issues Presentation to: NorthEast Cerebrovascular Consortium

Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

African Americans & Cardiovascular Diseases

Hot Line Session at European Society of Cardiology (ESC) Congress 2014:

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Current Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, ESRD Registry Committee, Korean Society of Nephrology*

Evaluation of Warfarin versus Aspirin on the Incidence of Thromboembolic Complications in Patients with Nonvalvular Atrial Fibrillation Final Paper

5. Management of rheumatic heart disease

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Your Guide to Express Critical Illness Insurance Definitions

ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014

Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation

Atrial Fibrillation The Basics

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

DEVELOPMENT AND VALIDATION OF AN INSTRUMENT TO ASSESS GENERAL KNOWLEDGE OF STROKE

INTRODUCTION TO EECP THERAPY

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

Investor News. Not intended for U.S. and UK media

Backgrounder. Current anticoagulant therapies

Adult Cardiac Surgery ICD9 to ICD10 Crosswalks

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE

LIPID PANEL CHOLESTEROL LIPOPROTEIN, ELECTROPHORETIC SEPARATION LIPOPROTEIN, DIRECT MEASUREMENT (HDL) LDL DIRECT TRIGLYCERIDES

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

Hot Topics: Current PFO Recommendations and Loop Monitoring/Cryptogenic Stroke.

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

Substandard Underwriting Structured Settlements

EXHIBIT H SETTLEMENT ELIGIBILITY CRITERIA. a) pharmacy records reflecting the dispensing of Bextra and/or Celebrex to the Class Member; or

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014

Transcription:

A Comparison of Infarct Size and Prognosis between Cardiogenic Embolic Infarction and Large Artery Atherosclerotic Infarction Ji-Hoon Jang, M.D., Byung-Woo Yoon, M.D.*, Jae-Kyu Roh, M.D.* Department of Neurology, Cheju Hanmaeum Hospital Department of Neurology, College of Medicine, Seoul National University*, Neuroscience Research Institute, SNUMRC Background : Cardiogenic embolic infarction is the most preventable type of ischemic stroke. This study was undertaken to compare the infarct size, prognosis, and risk factors between cardiogenic embolic infarction (CE) and large artery atherosclerotic infarction (LAA). M e t h o d s : We reviewed the medical records and brain computed tomography/magnetic resonance image (CT/MRI) scans of patients with CE or LAA during the period between January 1996 and May 1998. Patients with lacunar and posterior circulation infarctions were excluded. A slice of brain CT/MRI scan showing the largest lesion was selected in each patient and the area of infarction was then measured. Prognosis was determined by the Modified Rankin Disability Scale (MRDS) and was grouped as either good (MDRS 0, 1, 2) or poor (MDRS 3, 4, 5). Results : The study included 103 patients : 50 with CE (NVAF in 23, VHD with or without AF in 13, prosthetic valve in 6, and others in 8) and 53 with LAA (large artery thrombosis in 29, and artery to artery embolism in 24). The infarct size of CE (23.2±14.7 cm 2 ) was significantly larger than that of LAA (11.4±10.5 cm 2 ) (p<0.001). The infarct size of NVAF (29.0±19.1 cm 2 ) was significantly larger than that of VHD with or without AF (19.2±11.5 cm 2 ) (p<0.05). Patients with CE had a worse prognosis (poor in 46%) than those with LAA (poor in 23%) (p<0.05). C o n c l u s i o n s : Our results showed that CE led to larger lesions and worse outcomes. Therefore, we emphasize the importance of primary and secondary preventions of stroke in patients with cardiogenic embolic sources. J Korean Neurol Assoc 18(4):381~385, 2000 Key Words : Cardiogenic embolic infarction, Large artery atherosclerotic infarction, Nonvalvular atrial fibrillation, Valvular heart disease, Infarct size, Prognosis Byung-Woo Yoon, M.D. Copyright 2000 by the Korean Neurological Association 381

382 J Korean Neurol Assoc / Volume 18 / July, 2000

Table 1. Comparison between CE and LAA patients Factors CE(N=50) LAA(N=53) p value Male 27(54.0%) 42(79.2%) <0.01 Mean agesd(yr) 57.4±16.7 63.3±12.4 <0.05 Smoking 13(26.0%) 31(58.4%) <0.001 Infarct size(cm 2 ) 23.2±14.7 11.4±10.5 <0.001 Poor prognosis 23(46.0%) 12(23.0%) <0.05 LA size(mm) 49.6±15.7 39.4±6.4 <0.001 LV EF(%) 51.7±10.6 59.9±8.4 <0.001 hypercholesterolemia, diabetes mellitus, hematocrit, hypertension ; p >0.05 CE; cardioembolism, LAA; large artery atherosclerosis LA; left atrium, LV; left ventricle, EF; ejection fraction Table 2. Comparison between patients with NVAF and VHD with/without AF Factors NVAF(N=23) VHD±AF(N=13) p value Male 15(65.2%) 5(38.5%) NS Mean agesd(yr) 65.0±13.6 50.2±14.3 <0.01 Smoking 16(69.6%) 5(38.5%) <0.01 Infarct size(cm 2 ) 29.0±19.1 19.2±11.5 <0.01 Poor prognosis 14(60.9%) 6(46.2%) NS LA size(mm) 50.1±19.6 52.1±10.9 NS LV EF(%) 48.8±11.8 55.0±7.7 NS hypercholesterolemia, diabetes mellitus, hematocrit, hypertension ; p >0.05 NVAF; nonvalvular atrial fibrillation, VHD; valvular heart disease, AF; atrial fibrillation LA; left atrium, LV; left ventricle, EF; ejection fraction J Korean Neurol Assoc / Volume 18 / July, 2000 383

11. Cerebral Embolism Task Force. Cardiogenic Embolism. Brain 1986;43:71-84. 12. Moss AJ. Atrial fibrillation and cerebral embolism(editorial). Arch Neurol 1984;41:707. 384 J Korean Neurol Assoc / Volume 18 / July, 2000

13. Wolf PA, Dawber TR, Thomas HE, Kennel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. N e u r o l o g y 1 9 7 8 ; 2 8 : 9 7 3-9 7 7. 14. Yoon BW, Kim BK, Roh JK. How well do prevent cardioembolic stroke?. J Korean Neurol Assoc 1 9 9 6 ; 1 4 ( 1 ) : 1-8. 15. Yoon BW. Cardiac disease as risk factor of stroke. J Korean Neurol Assoc 1997;15:(Supp 2):31-43. 16. Yamanouchi H, Tomonaga M, Shimada H, et al. Nonvalvular atrial fibrillation as a cause of fatal massive cerebral infarction in the elderly. Stroke 1989;20:1653-1656. 17. Kaasrisalo MM, Marttila RJ, Salomaa V. Atrial fibrillation and Stroke:Mortality and causes of death after the first acute ischemic stroke. Stroke 1997;28:311-315. 18. Bogousslavsky J, Cachin C, Regli F, Despland PA, Van Melle G, Kappenberger L. Cardiac sources of embolism and cerebral infarction-clinical consequences and vascular concomitants:the Lausanne Stroke Registry. N e u r o l o g y 1 9 9 1 ; 4 1 : 8 5 5-8 5 9. 19. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial. S t r o k e 1 9 9 3 ; 2 4 : 3 5-4 1. 10. Timsit SG, Sacco RL, Mohr JP, Brain infarction severity differs according to cardiac or arterial embolic source. Neurology 1993;43:728-733. 11. Rankin J.Cerebral vascular accidents in patients over the age of 60: prognosis. Scott Med J 1957;2:200-215. 12. van Swieten JC, Koudstall PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607. 13. Cerebral Embolism Task Force. Cardiogenic embolism: the second report of the cerebral embolism task force. Arch Neurol 1989;46:727-743. 14. The Korean Neurological Association. Epidemiology of cerebrovascular disease in Korea.-A collaborative study, 1989-1990- J Kor Med Sci 1993;8:281-285. 15. Jeong SC, Lee BC, Kim HC et al. The Hallym stroke registry: Analysis of 1,129 consecutive patients with acute stroke(abstract). J Korean Neurol Assoc 1998;16(suppl. 2): 1 0. 16. Lin HJ, Wolf PA, Kase CS. Stroke severity in atrial fibrillation:the Framigham Study. Stroke 1996;27:1760-1764. 17. Wolf PA, Kannel WB, McGee DL. Atrial fibrillation and stroke in the elderly: the Framingham Study(abstract). S t r o k e 1 9 8 5 ; 1 6 : 1 3 8. 18. Keller TS, McGillicuddy JE, LaBond VA, Kindt GW. Volume expansion in focal cerebral blood flow. Clin Neurosurg 1982;29:40-50. 19. Lavy S, Stern S, Melamed E, Cooper G, Keren A, Levy P. Effect of chronc atrial fibrillation on regional cerebral blood flow. S t r o k e 1 9 8 0 ; 1 1 : 3 5-3 8. 20. Lee SH, Lee H, Lim JK, Lee SD, Park YC. Stroke as a late complication in patients with cardiac prosthetic valve. J Korean Neurol Assoc 1998;16(4):444-449. 21. Probst P, Goldschlager N, Selzer A. Left atrial size and atrial fibrillation in mitral stenosis. C i r c u l a t i o n 1 9 8 3 ; 48:1282-1287. 22. Adams GF, Merrett JD, Hutchinson WM, Pollock AM. Cerebral embolism and mitral stenosis: survival with and without anticoagulants. J Neurol Neurosurg Psychiatry 1974;37:378-383. 23. Caplan LR, Hier DB, Reddy H, Atrial size, atrial fibrillation, and stroke. Ann Neurol 1986;19:158-161. 24. Feinberg WM. Anticoagulation for prevention of stroke. Neurology 1998;51(Supp 3):S20-S22. 25. EAFT(European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischemic attack or minor stroke. L a n c e t 1993;342:1255-1265. J Korean Neurol Assoc / Volume 18 / July, 2000 385